Epitalon (AEDG) is a synthetic tetrapeptide consisting of alanine, glutamic acid, aspartic acid, and glycine. It is utilized as a molecular research tool in laboratory investigations focused on genome regulation, chromatin structure, and peptide–DNA interactions. Due to its minimal size and linear conformation, Epitalon is frequently studied in controlled experimental systems evaluating peptide-driven modulation of cellular regulatory pathways.

This material is provided exclusively for research use in non-clinical laboratory environments, including in-vitro systems and in-vivo animal models.

Amino Acid Sequence: Ala–Glu–Asp–Gly (AEDG)
Molecular Formula: C₁₄H₂₂N₄O₉
Molecular Weight: 390.349 g/mol
PubChem CID: 219042
CAS Number: 307297-39-8
Synonyms: Epithalon, Epithalone, Epithalamin, Epithalamine, AEDG

Source: PubChem

The peptide exhibits no tertiary folding due to its short chain length. This structural simplicity supports reproducible interaction studies with nucleic acids, transcriptional regulators, and chromatin-associated protein complexes in laboratory research settings.

Epitalon is employed in experimental research to examine peptide-mediated regulation of gene expression, telomere-associated processes, circadian gene signaling, and cellular differentiation pathways. Its physicochemical profile makes it suitable for studies involving formulation modeling, cellular uptake, and mechanistic evaluation in preclinical experimental models.

• Epigenetic regulation and chromatin accessibility studies
• Telomerase-associated pathway investigations
• Circadian rhythm gene expression research
• Neuronal and fibroblast differentiation models
• Peptide–genome interaction analysis

Preclinical studies suggest that Epitalon interacts directly with genomic DNA, influencing chromatin conformation and transcriptional regulation. Experimental data indicate modulation of telomerase-related mechanisms, regulation of circadian clock genes such as PER1, and interaction with transcriptional networks governing cell cycle dynamics.

At the molecular level, AEDG peptides have been observed to alter transcriptional activity through sequence-specific interactions, impacting histone-associated chromatin states and downstream gene expression profiles in experimental cellular and animal models.

In-vitro and in-vivo animal studies have evaluated Epitalon in the context of telomere maintenance, circadian signaling, neuronal marker expression, extracellular matrix regulation, and gene transcription control. Rodent and non-human primate models have been utilized to explore its influence on peptide-driven regulatory networks at the cellular and tissue levels.

Additional investigations have examined Epitalon within experimental oncology models, focusing on transcriptional regulation, cell proliferation signaling, and genomic stability pathways. All observations remain confined to preclinical exploratory research frameworks.

Epitalon is supplied as a laboratory-grade peptide for analytical and experimental use. Identity and purity may be assessed using standard laboratory methodologies including high-performance liquid chromatography (HPLC), mass spectrometry (MS), and amino acid composition analysis.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Epitalon. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

1. J. Shaji and V. Patole, “Protein and Peptide Drug Delivery: Oral Approaches,” Indian J. Pharm. Sci., vol. 70, no. 3, pp. 269–277, 2008, doi: 10.4103/0250-474X.42967.
2. V. Kh. Khavinson, I. E. Bondarev, and A. A. Butyugov, “Epitalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells,” Bull. Exp. Biol. Med., vol. 135, no. 6, Art. no. 6, Jun. 2003, doi: 10.1023/A:1025493705728.
3. T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaĭozishvili, M. A. Rogava, and T. A. Lazhava, “[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)],” Georgian Med. News, no. 225, Art. no. 225, Dec. 2013.
4. N. I. Chalisova, N. S. Lin’kova, A. N. Zhekalov, A. O. Orlova, G. A. Ryzhak, and V. K. Khavinson, “[Short peptides stimulate skin cell regeneration during ageing],” Adv. Gerontol. Uspekhi Gerontol., vol. 27, no. 4, pp. 699–703, 2014.
5. V. Khavinson et al., “AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism,” Mol. Basel Switz., vol. 25, no. 3, p. E609, Jan. 2020, doi: 10.3390/molecules25030609.
6. T. D. Brown, K. A. Whitehead, and S. Mitragotri, “Materials for oral delivery of proteins and peptides,” Nat. Rev. Mater., vol. 5, no. 2, Art. no. 2, Feb. 2020, doi: 10.1038/s41578-019-0156-6.
7. “Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. – NeL.edu.” https://www.nel.edu/pineal-regulating-tetrapeptide-epitalon-improves-eye-retina-condition-in-retinitis-pigmentosa-2210/ (accessed Nov. 15, 2022).
8. V. N. Anisimov et al., “Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice,” Int. J. Cancer, vol. 101, no. 1, pp. 7–10, Sep. 2002, doi: 10.1002/ijc.10570.
9. V. N. Anisimov, V. K. Khavinson, I. N. Alimova, A. V. Semchenko, and A. I. Yashin, “Epitalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice,” Bull. Exp. Biol. Med., vol. 134, no. 2, pp. 187–190, Aug. 2002, doi: 10.1023/a:1021104819170.
10. S. Gery, N. Komatsu, L. Baldjyan, A. Yu, D. Koo, and H. P. Koeffler, “The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells,” Mol. Cell, vol. 22, no. 3, pp. 375–382, May 2006, doi: 10.1016/j.molcel.2006.03.038.
11. V. Kh. Khavinson, L. K. Shataeva, and A. A. Chernova, “Effect of Regulatory Peptides on Gene Transcription,” Bull. Exp. Biol. Med., vol. 136, no. 3, pp. 288–290, Sep. 2003, doi: 10.1023/B:BEBM.0000008986.02891.de.
12. O. Korkushko et al., “[Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people],” Adv. Gerontol. Uspekhi Gerontol. Ross. Akad. Nauk Gerontol. Obshchestvo, vol. 20, pp. 74–85, Feb. 2007.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.